Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

FUSION PHARMACEUTICALS

🇳🇵Nepal

Country: 🇳🇵Nepal

Ownership: -

Employees: -

Market Cap: $1.8B

Website: https://fusionpharma.com/

Clinical Trials

FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase 2

Recruiting

Conditions: Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: FPI-2265
Drug: Olaparib

First Posted Date: 2025-04-04

Last Posted Date: 2025-05-29

Lead Sponsor: Fusion Pharmaceuticals Inc.

Target Recruit Count: 85

Registration Number: NCT06909825

Locations: 🇦🇺
St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia
🇦🇺
Macquarie University Hospital, Macquarie Park, New South Wales, Australia
🇦🇺
Icon Cancer Centre North Lakes, North Lakes, Queensland, Australia

and more 5 locations

FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase 2

Recruiting

Conditions: Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: FPI-2265

First Posted Date: 2024-05-07

Last Posted Date: 2025-04-25

Lead Sponsor: Fusion Pharmaceuticals Inc.

Target Recruit Count: 100

Registration Number: NCT06402331

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Hoag Health Center Irvine, Irvine, California, United States
🇺🇸
VA Greater Los Angeles Healthcare System, Los Angeles, California, United States

and more 15 locations

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

Phase 1

Recruiting

Conditions: Advanced Solid Tumor
Non-small Cell Lung Cancer
Metastatic Colorectal Carcinoma
Head and Neck Squamous Cell Carcinoma
Pancreatic Ductal Adenocarcinoma

Interventions: Drug: FPI-2053
Drug: [111In]-FPI-2107
Drug: [225Ac]-FPI-2068

First Posted Date: 2023-11-27

Last Posted Date: 2025-05-13

Lead Sponsor: Fusion Pharmaceuticals Inc.

Target Recruit Count: 110

Registration Number: NCT06147037

Locations: 🇺🇸
Hoag Hospital, Irvine, California, United States
🇺🇸
UCLA Medical Center, Santa Monica, California, United States
🇺🇸
Stanford Hospital and Clinics, Stanford, California, United States

and more 12 locations

A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

Phase 1

Active, not recruiting

Conditions: Gastric Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
Colorectal Cancer
Squamous Cell Carcinoma of Head and Neck
Neuroendocrine Differentiated (NED) Prostate Cancer
Ewing Sarcoma
NTSR1 Expressing Solid Tumours

Interventions: Drug: [225]-FPI-2059
Drug: [111In]-FPI-2058

First Posted Date: 2022-11-04

Last Posted Date: 2025-01-28

Lead Sponsor: Fusion Pharmaceuticals Inc.

Target Recruit Count: 42

Registration Number: NCT05605522

Locations: 🇺🇸
University of Alabama at Birmingham Hospital, Birmingham, Alabama, United States
🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
Hoag Family Cancer Institute, Newport Beach, California, United States

and more 5 locations

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Phase 1

Terminated

Conditions: Bladder Carcinoma
Head and Neck Squamous Cell Carcinoma
Susceptible FGFR3 Genetic Alterations
Breast Cancer
FGFR3 Receptor
FGFR3 Protein Overexpression
Colorectal Cancer
Liver Cancer
Advanced Solid Tumor
FGFR3

Interventions: Drug: [225Ac]-FPI-1966
Drug: [111In]-FPI-1967
Biological: vofatamab

First Posted Date: 2022-05-06

Last Posted Date: 2023-12-19

Lead Sponsor: Fusion Pharmaceuticals Inc.

Target Recruit Count: 6

Registration Number: NCT05363605

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

and more 3 locations

Targeted Alpha Therapy with 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).

Phase 2

Active, not recruiting

Conditions: Metastatic Castration Resistant Prostate Cancer

Interventions: Drug: FPI-2265

First Posted Date: 2022-02-02

Last Posted Date: 2025-02-13

Lead Sponsor: Fusion Pharmaceuticals Inc.

Target Recruit Count: 115

Registration Number: NCT05219500

Locations: 🇺🇸
XCancer Omaha/Urology Cancer Center, Omaha, Nebraska, United States
🇺🇸
Excel Diagnostics and Nuclear Oncology Center, Houston, Texas, United States

A Phase 1/2 Study of [225Ac]-FPI-1434 Injection

Phase 1

Recruiting

Conditions: Advanced Solid Tumours
Endometrial Cancer
Breast Cancer
Triple Negative Breast Cancer (TNBC)
Cervical Cancer
Ovarian Cancer
HER2-negative Breast Cancer
Adrenocortical Carcinoma
Uveal Melanoma
Head and Neck Squamous Cell Carcinoma (HNSCC)

Interventions: Drug: [111In]-FPI-1547 Injection
Drug: [225Ac]-FPI-1434 Injection single-dose
Drug: [225Ac]-FPI-1434 Injection multi-dose
Biological: FPI-1175 Infusion

First Posted Date: 2018-11-19

Last Posted Date: 2025-04-16

Lead Sponsor: Fusion Pharmaceuticals Inc.

Target Recruit Count: 253

Registration Number: NCT03746431

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

and more 10 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy